Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-613 in Acute Gouty Arthritis
CTR20222869Phase 2Completed
- Sponsor
- Henlius
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSGJ-613 in acute gout flare (3 arms), sponsored by Henlius. Primary endpoint: Change from baseline in target joint pain intensity assessed by 0-100 mm Visual Analog Scale (VAS) at 72 hours post-dose. Started Nov 2022; status: completed.
02
Drugs
SSGJ-613
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20222869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222869.